SubsidieMeestersApTOLL: An innovative neuroprotectant to reduce brain damage in Acute Ischemic Stroke (AIS)
The project aims to conduct a Phase 2b trial of ApTOLL, a novel neuroprotectant for acute ischemic stroke, to reduce brain damage and improve outcomes, targeting a multi-billion euro market.
Projectdetails
Introduction
Stroke is a devastating medical condition affecting 15 million people worldwide yearly, with Ischemic Stroke being the most frequent (87%). Indeed, the global cost of stroke is >€847 billion (≈€60 billion in the EU) due to the huge socioeconomic burden of disabilities.
Current Treatment Challenges
Reperfusion treatment improves outcomes, but only ≈20% of patients are currently eligible for treatment. This is due to the narrow therapeutic window after stroke symptom onset and stringent selection criteria for eligibility. Novel therapies, including small molecules or biologics targeting neuroprotection, have not achieved enough efficacy to gain approval.
ApTOLL Development
aptaTargets has successfully developed ApTOLL, an immune modulator and neuroprotectant with a novel approach to reduce brain damage in Acute Ischemic Stroke (AIS) patients. ApTOLL targets TLR4 to achieve:
- A 47% reduction of FIV
- Reduction of mortality from 18% to 4%
- Improvement of functional outcomes
Due to the innovative mode of action and nature of the molecule (an aptamer), ApTOLL represents a novel and disruptive approach to treating stroke in the first hours after onset (acute phase). This substantially reduces brain damage and improves Quality of Life (QoL) in both the short and long term.
Market Potential
ApTOLL is targeting the multi-billion market of the global Stroke Management Market, which was valued at €31.7 billion in 2020 and is expected to reach €67.7 billion in 2030 (7.8% CAGR). As a first indication within the scope of this EIC Accelerator proposal, ApTOLL will target AIS patients (87%) who received EVT therapy, with the expectation of being potentially used as a neuroprotectant in all stroke patients, based on preclinical and clinical results.
EIC Project Goals
The EIC project aims to conduct the Phase 2b trial of ApTOLL and demonstrate its efficacy before entering Phase 3. This will boost our chances of licensing the product to a pharmaceutical company, thereby increasing the value of the agreement.
Financiële details & Tijdlijn
Financiële details
| Subsidiebedrag | € 2.498.816 |
| Totale projectbegroting | € 3.569.737 |
Tijdlijn
| Startdatum | 1-1-2024 |
| Einddatum | 31-3-2026 |
| Subsidiejaar | 2024 |
Partners & Locaties
Projectpartners
- APTATARGETS SLpenvoerder
Land(en)
Vergelijkbare projecten binnen EIC Accelerator
| Project | Regeling | Bedrag | Jaar | Actie |
|---|---|---|---|---|
BraiN20®: A paradigm shift in Acute Ischemic Stroke (AIS) patient managementBraiN20 is a non-invasive device that monitors brain viability in AIS patients to enhance EVT decision-making and improve treatment outcomes through real-time data. | EIC Accelerator | € 2.500.000 | 2023 | Details |
APAC – the first targeted therapy for peripheral arterial occlusive disease.Aplagon is developing APAC, a targeted therapy for advanced peripheral arterial occlusive disease, aiming to improve safety and efficacy in clinical studies to address high morbidity and mortality rates. | EIC Accelerator | € 2.099.387 | 2022 | Details |
EDV2209 – a Paradigm shift in the treatment of stroke.Edvince aims to revolutionize stroke treatment with its innovative drug EDV2209, enhancing cerebral blood flow to prevent brain damage from severe subarachnoid hemorrhage. | EIC Accelerator | € 2.500.000 | 2022 | Details |
To deliver the first medical treatment dedicated to patients with haemorrhagic strokeNANOp2lysis develops O2L-001, a safe, effective thrombolytic agent for intracerebral hematoma treatment via a single injection, enhancing delivery and reducing side effects post-hemorrhagic stroke. | EIC Accelerator | € 2.500.000 | 2022 | Details |
PAH-ADVANCE: Accelerating the Clinical Path of NTP42, a disease-modifying drug that will disrupt the future treatment of cardiopulmonary diseases, including pulmonary arterial hypertension (PAH).ATXA Therapeutics aims to advance NTP42, a novel drug for pulmonary arterial hypertension, through Phase II trials and licensing to accelerate market entry and diversify its drug portfolio. | EIC Accelerator | € 2.500.000 | 2023 | Details |
BraiN20®: A paradigm shift in Acute Ischemic Stroke (AIS) patient management
BraiN20 is a non-invasive device that monitors brain viability in AIS patients to enhance EVT decision-making and improve treatment outcomes through real-time data.
APAC – the first targeted therapy for peripheral arterial occlusive disease.
Aplagon is developing APAC, a targeted therapy for advanced peripheral arterial occlusive disease, aiming to improve safety and efficacy in clinical studies to address high morbidity and mortality rates.
EDV2209 – a Paradigm shift in the treatment of stroke.
Edvince aims to revolutionize stroke treatment with its innovative drug EDV2209, enhancing cerebral blood flow to prevent brain damage from severe subarachnoid hemorrhage.
To deliver the first medical treatment dedicated to patients with haemorrhagic stroke
NANOp2lysis develops O2L-001, a safe, effective thrombolytic agent for intracerebral hematoma treatment via a single injection, enhancing delivery and reducing side effects post-hemorrhagic stroke.
PAH-ADVANCE: Accelerating the Clinical Path of NTP42, a disease-modifying drug that will disrupt the future treatment of cardiopulmonary diseases, including pulmonary arterial hypertension (PAH).
ATXA Therapeutics aims to advance NTP42, a novel drug for pulmonary arterial hypertension, through Phase II trials and licensing to accelerate market entry and diversify its drug portfolio.
Vergelijkbare projecten uit andere regelingen
| Project | Regeling | Bedrag | Jaar | Actie |
|---|---|---|---|---|
The pursuit of non-invasive treatment for intracranial aneurysms to PRevent aneurYSMal subarachnoid hemorrhageThe Treat-PRYSM project aims to validate and repurpose five candidate drugs to prevent aSAH in unruptured intracranial aneurysms by targeting the EndMT and TGF- pathways, with a focus on sex-specific effects. | ERC Proof of... | € 150.000 | 2025 | Details |
Targeting the Imidazoline I1 receptor as a novel treatment for AtherosclerosisImnovAth aims to develop a novel therapy targeting a microbiota-derived metabolite to enhance atherosclerosis treatment efficacy and advance towards clinical trials and commercialization. | ERC Proof of... | € 150.000 | 2024 | Details |
Targeting Acute Leukemia with TdT-TCR-T-cell therapyThis project aims to commercialize a novel T-cell receptor therapy for acute lymphoblastic leukemia, demonstrating efficacy in pre-clinical models, with plans for a clinical trial and market analysis. | ERC Proof of... | € 150.000 | 2023 | Details |
Project MITH Nico.labDit project onderzoekt de haalbaarheid van EEG-herseninfarct triage in ambulances met AI-algoritmen om snel en nauwkeurig patiënten te identificeren voor directe behandeling. | Mkb-innovati... | € 20.000 | 2020 | Details |
Pushing Boundaries in Pre-clinical Aortopathy ResearchThis project aims to unravel mechanisms of syndromic thoracic aortic aneurysm and develop effective therapies using patient-derived aorta-on-a-chip models for pre-clinical research. | ERC Starting... | € 1.494.848 | 2024 | Details |
The pursuit of non-invasive treatment for intracranial aneurysms to PRevent aneurYSMal subarachnoid hemorrhage
The Treat-PRYSM project aims to validate and repurpose five candidate drugs to prevent aSAH in unruptured intracranial aneurysms by targeting the EndMT and TGF- pathways, with a focus on sex-specific effects.
Targeting the Imidazoline I1 receptor as a novel treatment for Atherosclerosis
ImnovAth aims to develop a novel therapy targeting a microbiota-derived metabolite to enhance atherosclerosis treatment efficacy and advance towards clinical trials and commercialization.
Targeting Acute Leukemia with TdT-TCR-T-cell therapy
This project aims to commercialize a novel T-cell receptor therapy for acute lymphoblastic leukemia, demonstrating efficacy in pre-clinical models, with plans for a clinical trial and market analysis.
Project MITH Nico.lab
Dit project onderzoekt de haalbaarheid van EEG-herseninfarct triage in ambulances met AI-algoritmen om snel en nauwkeurig patiënten te identificeren voor directe behandeling.
Pushing Boundaries in Pre-clinical Aortopathy Research
This project aims to unravel mechanisms of syndromic thoracic aortic aneurysm and develop effective therapies using patient-derived aorta-on-a-chip models for pre-clinical research.